Trace Neuroscience

Trace Neuroscience develops genomic therapies for ALS. Its lead antisense oligonucleotide restores UNC13A function to improve muscle performance.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2024
Trace neuro Hover Image